TLDR
- Tempus AI (TEM) dropped 7.33% on the day the USC Keck Medicine partnership was announced
- The collaboration covers 1.5 million+ annual patient visits across USC’s Southern California network
- The deal includes genomic profiling, clinical trial matching, AI care gap tools, and research development
- TEM has posted 83% revenue growth over 12 months but remains unprofitable at -$1.41 EPS
- TD Cowen recently upgraded TEM to Buy, while Jefferies initiated with an Underperform rating
Tempus AI announced a multi-part collaboration with Keck School of Medicine of USC and Keck Medicine of USC on April 23, aimed at weaving AI and data analytics into patient care across USC’s healthcare network.
The partnership spans more than 1.5 million annual patient visits, covering USC Norris Comprehensive Cancer Center, Keck Hospital of USC, USC Verdugo Hills, and affiliated clinics across Southern California.
The deal is built around four pillars. First, molecular diagnostics and genomic profiling will be integrated directly into Keck Medicine’s clinical workflows.
Second, Tempus’ TIME Trial Program will be used to match patients with eligible clinical trials. Third, AI tools will be deployed to identify gaps in patient care pathways. Fourth, both parties will collaborate on developing new AI tools that link research to real-world clinical care.
Vasiliki Anest, Chief Innovation Officer at Keck School of Medicine of USC, said the goal is to align research, clinical care, and innovation priorities around the patient.
Ezra Cohen, Chief Medical Officer of Oncology at Tempus, framed the deal as building an integrated ecosystem combining Tempus’ AI platform with USC’s research and clinical depth.
Despite the strategic news, TEM stock fell 7.33% on the day, closing at $51.44.
Financials in Focus
Tempus carries a market cap of around $9.95 billion. Revenue has grown 83% over the last twelve months, which is hard to ignore. But the company is still burning cash, with a loss of $1.41 per share and no profitability expected this year, according to analyst estimates.
The current ratio sits at 3.13, and gross profit margins are healthy at 63%, suggesting the underlying business model has legs even if the bottom line hasn’t caught up yet.
Analyst Divide
Wall Street is split on TEM right now. TD Cowen upgraded the stock to Buy from Hold, pointing to stronger company fundamentals despite a rough six-month stretch for the stock.
Jefferies went the other way, initiating coverage with an Underperform rating. Their concern centers on an unclear catalyst path in therapy selection compared to peers.
The stock had already taken a hit earlier when OpenAI launched GPT-Rosalind, an AI model targeting drug discovery — a space that overlaps with Tempus’ core business.
On the partnership front, Tempus has been active. The company recently expanded a multi-year deal with Gilead Sciences, giving Gilead access to Tempus’ AI-driven Lens platform to support its oncology pipeline.
Tempus also teamed up with Predicta Biosciences to offer a co-branded whole-genome sequencing assay for blood cancers, pulling genomic data from peripheral blood or bone marrow samples.
TEM closed at $51.44, down $4.07 on the day of the USC announcement.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
